MVCCOV-1901 is under clinical development by Medigen Vaccine Biologics and currently in Phase II for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase II drugs for Coronavirus Disease 2019 (COVID-19) have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MVCCOV-1901’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MVCCOV-1901 overview
MVCCOV-1901 is under development for the prevention of coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is administered through intramuscular route. The vaccine candidate comprises of viral spike protein and is being developed based on recombinant spike protein technology.
Medigen Vaccine Biologics overview
Medigen Vaccine Biologics (MVC), a subsidiary of Medigen Biotechnology Corp, is a biopharmaceutical company. It primarily focuses on the development and mass production of vaccines and biologics. The company’s main activities include research and development, with a particular emphasis on global and regional infectious diseases, and the production of vaccines using cell culture technology. MVC’s products include the MVC COVID-19 vaccine, enterovirus A17 vaccine, and dengue vaccine. The company’s products are primarily used in the healthcare industry for the prevention and treatment of emerging infectious diseases. MVC is headquartered in Taipei, Taiwan.
For a complete picture of MVCCOV-1901’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.